Journal of Family and Reproductive Health 2016. 10(4):165-175.

Role of Statin Drugs for Polycystic Ovary Syndrome
Lisa Cassidy Vu, Edwina Joe, Julienne K Kirk

Abstract


Objective: To review the potential role and specific impact of statin drugs in women with PCOS. The evidence for this use of statins in PCOS is limited and still under further investigation.
Materials and methods: A search was conducted using PubMed, DynaMed and PubMedHealth databases through October 16, 2016 using the terms polycystic ovary syndrome, PCOS, hydroxymethylglutaryl-coa reductase inhibitors, hydroxymethylglutaryl-coa, statin, atorvastatin, fluvastatin, lovastatin, pitavastatin, pravastatin, rosuvastatin and simvastatin. English-language trials evaluating statins in PCOS were obtained and incorporated if they provided relevant data for providers.
Results: We summarize twelve trials involving statins in PCOS. The trials were predominantly 12 weeks to 3 months in length (8 of the 12 trials) and low to moderate dose of statin drugs were used. The majority (10 of 12) of the trials show that statins reduce testosterone levels or other androgen hormones (DHEA-S and androstenedione), half of the trials evaluating LH/FSH ratio show an improvement, and all had positive effects on lipid profiles.
Conclusion: Statins show promising improvements in serum levels of androgens and LH/FSH ratios translating to improved cardiovascular risk factors above and beyond simply lowering LDL levels. More investigation is needed to determine if statins can clinically impact women with PCOS long term, particularly those who are young and are not yet candidates for traditional preventative treatment with a statin medication.

 


Keywords


Polycystic Ovarian Syndrome; PCOS; Hydroxymethylglutaryl-coaReductase Inhibitors; Statin Drugs

Full Text:

PDF

References


Fauser BC, Tarlatzis BC, Rebar RW, Legro RS, Balen AH, Lobo R, et al. Consensus on women’s health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group. Fertil Steril 2012; 97:28-38.

ACOG Committee on Practice Bulletin No. 108: Polycystic ovary syndrome. Obstet Gynecol 2009; 114:936-49.

Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003consensus on diagnostic criteria and long-term health risks related to polycystic

ovary syndrome. Fertil Steril 2004; 81:19-25.

Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale HF, Futterweit W, et al. Positions statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline. Androgen Excess Society. J Clin Endocrinol Metab 2006; 91:4237-45.

Sirmans SM, Weidman-Evans E, Everton V, Thompson D. Polycystic ovary syndrome and chronic inflammation: pharmaco therapeutic implications. Ann Pharmacother 2012; 46:403-18.

Rizzo M, Berneis K. Who needs to care about small, dense low-density lipoproteins? Int J Clin Pract2007; 61:1949-56.

Apridonidze T, Essah PA, Iuorno MJ, Nestler JE. Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metab2005; 90:1929-35.

Repaci A, Gambineri A, Pasquali R. The role of low-grade inflammation in the polycystic ovary syndrome. Mol Cell Endocrinol 2011; 335:30-41.

Sathyapalan T, Atkin SL. Evidence for statin therapy in polycystic ovary syndrome. Ther Adv Endocrinol Metab 2010; 1:15-22.

Ferri N, Corsini A. Clinical evidence of statin therapy in non-dyslipidemic disorders. Pharmacol Res2014; 88:20-30.

Kodaman PH, Duleba AJ. HMG-CoA reductase inhibitors: do they have potential in the treatment of polycystic ovary syndrome? Drugs 2008; 68:1771-85.

Raval AD, Hunter T, Stuckey B, Hart RJ. Statins for women with polycystic ovary syndrome not actively trying to conceive. Cochrane Database Syst Rev 2011; 5:CD008565.

Gill SK. Cardiovascular risk factors and disease in women. Med Clin N Am 2015; 99:535-52.

Thompson PD, Panza G, Zaleski A, Taylor B. Statin-associated side effects. J Am Coll Cardiol 2016; 67:2395-410.

Duleba AJ, Banaszewska B, Spaczynski RZ, Pawelczyk L. Simvastatin improves biochemical parameters in women with polycystic ovary syndrome: results of a prospective, randomized trial. Fertil Steril 2006; 85:996-1001.

Banaszewska B, Pawelczyk L, Spaczynski RZ, Dziura J, Duleba AJ. Effects of simvastatin and oral contraceptive agent on polycystic ovary syndrome: prospective randomized cross-over trial. J Clin Endocrin Metab 2007; 92:456-61.

Banaszewska B, Pawelczyk L, Spaczynski RZ, Duleba AJ. Comparison of simvastatin and metformin in treatment of polycystic ovary syndrome: prospective randomized trial. J Clin Endocrinol Metab 2009; 94:4938-45.

Banaszewska B, Pawelczyk L, Spaczynski RZ, Duleba AJ. Effects of simvastatin and metformin on polycystic ovary syndrome after six months of treatment. J Clin Endocrinol Metab 2011; 96:3493-501.

Kazerooni T, Shojaei-Baghini A, Dehbashi S, Asadi N, Ghaffarpasand F, Kazerooni Y. Effects of metformin plus simvastatin on polycystic ovary syndrome: a prospective, randomized, double-blind, placebo-controlled study. Fertil Steril 2010; 94:2208-13.

Krysiak R, Zmuda W, Okopien B. The Effect of Ezetimibe on Androgen Production in Hypercholesterolemia Women with Polycystic Ovary Syndrome. Cardiovasc Ther 2014; 32:219-23.

Sathyapalan T, Kilpatrick ES, Coady AM, Atkin SL. The effect of atorvastatin in patients with polycystic ovary syndrome: a randomized double-blind placebo-controlled study. J Clin Endocrinol Metab 2009; 94:103-8.

Sathyapalan T, Smith KA, Coady AM, Kilpatrick ES, Atkin SL. Atorvastatin therapy decreases androstenedione and dehydroepiandrosterone sulphate concentrations in patients with polycystic ovary syndrome: randomized controlled study. Ann Clin Biochem 2012; 49:80-5.

Raja-Khan N, Kunselman AR, Hogeman CS, Stetter CM, Demers LM, Legro RS. Effects of atorvastatin on vascular function, inflammation, and androgens in women with polycystic ovary syndrome: a double-blind, randomized, placebo-controlled trial. Fertil Steril 2011; 95:1849-52.

Puurunen J, Piltonen T, Puukka K, Ruokonen A, Savolainen MJ, Bloigu R, et al. Statin therapy worsens insulin sensitivity in women with polycystic ovary syndrome (PCOS): a prospective, randomized, double-blind, placebo-controlled study. J Clin Endocrinol Metab 2013; 98:4798-807.

Kaya C, Cengiz SD, Berker B, Demirtaş S, Cesur M, Erdoğan G. Comparative effects of atorvastatin and simvastatin on the plasma total homocysteine levels in women with polycystic ovary syndrome: a prospective randomized study. Fertil Steril 2009; 92:635-42.

Ghazeeri G, Abbas HA, Skaff B, Harajly S, Awwad J. Inadequacy of initiating rosuvastatin then metformin on biochemical profile of polycystic ovarian syndrome patients. J Endocrinol Invest 2015; 38:643-51.

Yusuf S, Bosch J, Dagenais G, Zhu J, Xavier D, Liu L,

et al. Cholesterol lowering in intermediate risk persons without CVD. N Engl J Med 2016; 374:2021-31.

Taylor F, Huffman MD, Macedo A, Moore TH, Burke M, Davey Smith G, et al. Statins for primary prevention. Cochrane Database Syst Rev 2013; 31:CD004816.

McCartney CR, Marshall JC. Clinical practice. Polycystic ovary syndrome. N Engl J Med 2016; 375:54-64.

Gao L, Zhao FL, Li SC. Statin is a reasonable treatment option for patients with polycystic ovary syndrome: a meta-analysis of randomized controlled trials. Exp Clin Endocrinol Diabetes 2012; 120:367-75.

Valkenburg O, Steegers-Theunissen RP, Smedts HP, Dallinga-Thie GM, Fauser BC, Westerveld EH, et al. A more atherogenic serum lipoprotein profile is present in women with polycystic ovary syndrome: a case-control study. J Clin Endocrinol Metab 2008; 93:470-6.

Apridonidze T, Essah PA Iuorno MJ, Nestler JE. Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2005; 90:1929-35.

Fauser BC, Tarlatzis BC, Rebar RW, Legro RS, Balen AH, Lobo R, et al. Consensus on women’s health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group. Fertil Steril 2012; 97:

-38.

Duleba AJ. Medical management of metabolic dysfunction in PCOS. Steroids 2012; 77:306-11.

Bozdag G, Yildiz B. Interventions for the metabolic dysfunction in polycystic ovary syndrome. Steroids 2013; 78:777-81.

Kodaman PH, Duleba AJ. Statins in the treatment of polycystic ovary syndrome. Semin Reprod Med 2008; 26:127-38.

Lanham MS, Lebovic DI, Domino SE. Contemporary medical therapy for polycystic ovary syndrome. Int J Gynaecol Obstet 2006; 95:236-41.

Moreno LE, Bonnell A, Neher JO, Safranek S. Clinical inquiry: what therapies alleviate symptoms of polycystic ovary syndrome?. J FAM Pract 2015; 64:247-9.

Sathyapalan T, Kilpatrick ES, Coady AM, Atkin SL. Atorvastatin pretreatmentaugments the effect of metformin in patients with polycystic ovary syndrome (PCOS). Clin Endocrinol (Oxf) 2010; 72:566-8.


Refbacks

  • There are currently no refbacks.


Creative Commons Attribution-NonCommercial 3.0

This work is licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.